Table Filtering
Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
LM-GlycoRepo
Repository for lectin-assisted multimodality data
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / Organisms
GlycoNAVI Proteins
GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
| Source | Last Updated |
|---|---|
| GlycoNAVI Proteins | January 08, 2025 |
| PDB ID | UniProt ID | Title ▲ | Descriptor |
|---|---|---|---|
| 1TYE | P08514 | Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen | |
| 1TYE | P05106 | Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen | |
| 5VK2 | P08669 | Structural basis for antibody-mediated neutralization of Lassa virus | |
| 5VK2 | 5VK2 | Structural basis for antibody-mediated neutralization of Lassa virus | |
| 7C8K | E2DHI3 | Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to bat ACE2 | |
| 7N1Q | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1T | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1U | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1V | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1W | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1X | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 7N1Y | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
| 6NZK | Q696P8 | Structural basis for human coronavirus attachment to sialic acid receptors | |
| 6OHW | Q696P8 | Structural basis for human coronavirus attachment to sialic acid receptors. Apo-HCoV-OC43 S | |
| 3RKI | P03420 | Structural basis for immunization with post-fusion RSV F to elicit high neutralizing antibody titers | |
| 4ZG6 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | |
| 4ZG7 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | |
| 4ZG9 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | |
| 4ZGA | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | |
| 3ZS5 | Q16539 | Structural basis for kinase selectivity of three clinical p38alpha inhibitors | |
| 5NUP | D6QLY0 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
| 5NUP | A0A0W8AQT6 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
| 5NUR | P02931 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
| 5NUR | A0A0W8AQT6 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
| 7CAB | P0DTC2 | Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | |
| 6C0B | M4NKV9 | Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B | |
| 6C0B | Q14332 | Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B | |
| 2E33 | Q80UW2 | Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase | |
| 2E33 | P61823 | Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase | |
| 3A7Q | Q60841 | Structural basis for specific recognition of reelin by its receptors | |
| 3A7Q | Q14114 | Structural basis for specific recognition of reelin by its receptors | |
| 4EIR | Q1K8B6 | Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-2) | |
| 4EIS | Q7SA19 | Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-3) | polysaccharide monooxygenase-3 |
| 3S35 | 3S35 | Structural basis for the function of two anti-VEGF receptor antibodies | |
| 3S35 | P35968 | Structural basis for the function of two anti-VEGF receptor antibodies | |
| 3W9I | P52002 | Structural basis for the inhibition of bacterial multidrug exporters | |
| 3W9J | P52002 | Structural basis for the inhibition of bacterial multidrug exporters | |
| 5JT8 | A1KXI0 | Structural basis for the limited antibody cross reactivity between the mite allergens Blo t 1 and Der p 1 | |
| 5F1B | P87666 | Structural basis of Ebola virus entry: viral glycoprotein bound to its endosomal receptor Niemann-Pick C1 | |
| 5F1B | O15118 | Structural basis of Ebola virus entry: viral glycoprotein bound to its endosomal receptor Niemann-Pick C1 | |
| 4PGZ | P10721 | Structural basis of KIT activation by oncogenic mutations in the extracellular region reveals a zipper-like mechanism for ligand-dependent or oncogenic receptor tyrosine kinase activation | |
| 4ZH7 | Q9ZKV2 | Structural basis of Lewisb antigen binding by the Helicobacter pylori adhesin BabA | |
| 2OCV | P19221 | Structural basis of Na+ activation mimicry in murine thrombin | |
| 6TL8 | P20138 | Structural basis of SALM3 dimerization and adhesion complex formation with the presynaptic receptor protein tyrosine phosphatases | |
| 6TL8 | Q80XU8 | Structural basis of SALM3 dimerization and adhesion complex formation with the presynaptic receptor protein tyrosine phosphatases | |
| 7DRV | Q9BYF1 | Structural basis of SARS-CoV-2-closely-related bat coronavirus RaTG13 to hACE2 | |
| 7DRV | A0A6B9WHD3 | Structural basis of SARS-CoV-2-closely-related bat coronavirus RaTG13 to hACE2 | |
| 3S2K | O75581 | Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. | |
| 3S2K | O94907 | Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. | |
| 5LCV | A0A120IIH9 | Structural basis of Zika and Dengue virus potent antibody cross-neutralization |
